Journal
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Volume 1171, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jchromb.2021.122641
Keywords
COVID-19; SARS-CoV-2; Remdesivir; Mass spectrometry; Bioanalysis
Funding
- National Cancer Institute, National Institutes of Health [ZIA BC 011974]
Ask authors/readers for more resources
Remdesivir has been approved by the FDA as the first antiviral drug to treat COVID-19, and a rapid and sensitive LC-MS/MS assay has been developed for its quantification in human plasma with high accuracy and precision.
Remdesivir, formerly GS-5734, has recently become the first antiviral drug approved by the U.S. Food and Drug Administration (FDA) to treat COVID-19, the disease caused by SARS-CoV-2. Therapeutic dosing and pharmacokinetic studies require a simple, sensitive, and selective validated assay to quantify drug concentrations in clinical samples. Therefore, we developed a rapid and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma with its deuterium-labeled analog, remdesivir-2H5, as the internal standard. Chromatographic separation was achieved on a Phenomenex? SynergiTM HPLC Fusion-RP (100 ? 2 mm, 4 ?m) column by gradient elution. Excellent accuracy and precision (<5.2% within-run variations and. <9.8% between-run variations) were obtained over the range of 0.5?5000 ng/mL. The assay met the FDA Bioanalytical Guidelines for selectivity and specificity, and low inter-matrix lot variability (<2.7%) was observed for extraction efficiency (77%) and matrix effect (123%) studies. Further, stability tests showed that the analyte does not degrade under working conditions, nor during freezing and thawing processes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available